Abstract:Abstract Introduction: Despite the numerous drugs available for patients with metastatic colorectal cancer (mCRC), median overall survival for this group of patients remains at ~20-24 months, with no significant advances in the last 7 years. In the US ~50,000 patients die each year from mCRC refractory to systemic therapy. Inhibiting angiogenesis as a therapy has led to a great deal of enthusiasm. However, the overall benefit of classical-antiangiogenic therapy remains modest and has not lived up to their expectations in treating CRC. Our recent studies suggest that VEGF intracrine signaling, rather than autocrine/paracrine signaling, regulates cell survival in CRC cells. Further studies to understand the significance and mechanisms of this novel function have led us to identify factors that intracellularly interact with VEGF. Our studies further indicate that one such interacting protein, SPECC1L, may have a significant role in CRC cell proliferation and may be a potential target in mCRC therapy. Methods: Lysates from CRC cells expressing Myc-tagged VEGF protein were immunoprecipitated and analyzed by mass spectrometry to identify VEGF-interacting protiens. SPECC1L was identified as a co-precipitated protein with high level of confidence. SPECC1L was depleted using siRNA and effects of such depletion on CRC cell growth and morphology were measured by cell growth assays (MTT), microscopy, FACS and western blot analyses. Localization of the protein and its interaction with microtubules and actin were visualized by immunostaining of FLAG-tagged recombinant SPECC1L protein. Results: SPECC1L was identified as a protein that co-immunoprecipitated with Myc-tagged VEGF in CRC cells using mass spectroscopy. Previous literature suggests a role for SPECC1L in cell division. As a fraction of VEGF overexpressing CRC cells have a large multinucleated phenotype, likely arising due to defects in cell division, it was hypothesized that a VEGF mediated regulation of SPECC1L may lead to such phenotype. Depletion of SPECC1L by siRNAs in multiple CRC cell lines led to strong defects in cell division. The effects of SPECC1L depletion were manifested as accumulation of doublet-cells failing to complete cytokinesis following mitosis and resulted in reduced cell proliferation. Failure to complete cell division also led to the formation of multinucleated cells and enhanced cell death. Conclusions: Inhibition of SPECC1L strongly inhibits CRC cell proliferation and enhances cell death. Thus targeting SPECC1L has the potential for developing therapeutics that reduce viability of CRC cells and improve survival of colorectal cancer patients. *** These studies were supported by the Gillson-Longenbaugh Foundation. Citation Format: Rajat Bhattacharya, Ling Xia, Fan Fan, Rui Wang, Delphine Boulbes, Xiang-Cang Ye, David Hawke, Lee Ellis. Depletion of SPECC1L inhibits colorectal cancer cell proliferation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 3474. doi:10.1158/1538-7445.AM2017-3474

Knockdown of SPOCK1 Inhibits the Proliferation and Invasion in Colorectal Cancer Cells by Suppressing the PI3K/Akt Pathway

Abstract 3474: Depletion of SPECC1L Inhibits Colorectal Cancer Cell Proliferation

SPOCK1 Promotes the Proliferation, Migration and Invasion of Glioma Cells Through PI3K/AKT and Wnt/β-catenin Signaling Pathways.

SPOCK1 Promotes Tumor Growth and Metastasis in Human Prostate Cancer

SPOCK1 promotes metastasis in pancreatic cancer via NF-κB-dependent epithelial-mesenchymal transition by interacting with IκB-α

SPOCK1 is Regulated by CHD1L and Blocks Apoptosis and Promotes HCC Cell Invasiveness and Metastasis in Mice

SPOCK1 is a novel transforming growth factor-β target gene that regulates lung cancer cell epithelial-mesenchymal transition.

A novel FOXM1 isoform, FOXM1D, promotes epithelial–mesenchymal transition and metastasis through ROCKs activation in colorectal cancer

SPOCK1 As a Potential Cancer Prognostic Marker Promotes the Proliferation and Metastasis of Gallbladder Cancer Cells by Activating the PI3K/AKT Pathway

SPOCK: Master regulator of malignant tumors (Review)

SPOCK1 and POSTN Are Valuable Prognostic Biomarkers and Correlate with Tumor Immune Infiltrates in Colorectal Cancer

Assessment of the prognostic value of SPOCK1 in clear cell renal cell carcinoma: a bioinformatics analysis

Spock1/Six1axis Promotes Breast Cancer Progression By Activating Akt/Mtor Signaling

SPOCK1 promotes breast cancer progression via interacting with SIX1 and activating AKT/mTOR signaling pathway

Multiomic Analysis of the Function of SPOCK1 Across Cancers: an Integrated Bioinformatics Approach

Abstract 5309: Characterization of a Novel Oncogene SPOCK1 in Humanhepatocellular Carcinoma.

SPOCK1 Overexpression Suggests Poor Prognosis of Ovarian Cancer

SPOCK1 contributes to the third-generation EGFR tyrosine kinase inhibitors resistance in lung cancer.

SPOCK1 is a Prognostic-Related Biomarker and Correlated with Immune Infiltrates in Head and Neck Squamous Cell Carcinoma

MicroRNA-155-5p Inhibits the Invasion and Migration of Prostate Cancer Cells by Targeting SPOCK1

Speckle-Type POZ Protein Down-Regulates Matrix Metalloproteinase 2 Expression Via Sp1/PI3K/Akt Signaling Pathway in Colorectal Cancer